Your browser doesn't support javascript.
loading
Antipsychotic use in a large community sample of patients with delusional disorder.
Gonzalo-de Miguel, A; Abascal-Peiró, S; Cegla-Schvartzman, F B; Martínez-Alés, G; Baca-García, E.
Afiliación
  • Gonzalo-de Miguel A; Department of Psychiatry, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
  • Abascal-Peiró S; Department of Psychiatry, Rey Juan Carlos University Hospital, Móstoles, Spain.
  • Cegla-Schvartzman FB; Department of Psychiatry, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
  • Martínez-Alés G; CAUSALab, Harvard TH Chan School of Public Health, Boston, MA, USA; La Paz Research Institute (IdiPAZ), Madrid, Spain; CIBERSAM (Centro de Investigación Biomédica en Red Salud Mental), Carlos III Institute of Health, Madrid, Spain; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, N
  • Baca-García E; Department of Psychiatry, Fundación Jiménez Díaz University Hospital, Madrid, Spain; Department of Psychiatry, Rey Juan Carlos University Hospital, Móstoles, Spain; CIBERSAM (Centro de Investigación Biomédica en Red Salud Mental), Carlos III Institute of Health, Madrid, Spain; Department of Psychiat
Schizophr Res ; 271: 194-199, 2024 Sep.
Article en En | MEDLINE | ID: mdl-39032432
ABSTRACT

BACKGROUND:

To examine clinical and sociodemographic differences between patients with delusional disorder; with and without diagnoses of an additional severe mental disorder (SMD) or cognitive impairment.

METHODS:

Population-based study including all individuals diagnosed with DD between 2005 and 2021 from a large catchment area in Madrid, Spain. Sociodemographic and clinical characteristics and the antipsychotic prescription patterns of the study population was described. Patients were divided into (i) patients with DD and no additional diagnosis of SMD or cognitive impairment (DD group), (ii) patients with DD and a diagnosis of an additional SMD (DD-SMD group), and (iii) patients with DD and cognitive impairment (DD-CI group).

RESULTS:

Of 1109 patients with a DD diagnosis (62.5 % female), 131 (11.8 %) patients were diagnosed with an additional SMD, and 69 (6.2 %) were diagnosed with cognitive impairment. DD-SMD patients were on average 10 years younger and had longer time between first mental healthcare contact and DD disorder than DD patients. DD-CI patients were on average 10 years older and had a higher proportion of females. Paliperidone (21.9 %) and aripiprazole (20.6 %) were the modal antipsychotic drugs chosen overall. DD-SMD patients were more likely to receive paliperidone and to be prescribed long-acting injectable medication; DD-CI were more likely to receive risperidone or quetiapine; and DD patients were more likely to receive olanzapine.

CONCLUSIONS:

Sociodemographic and clinical characteristics and choice of antipsychotic drug and delivery method for individuals with DD vary based on its comorbidity.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esquizofrenia Paranoide / Antipsicóticos Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Schizophr Res Asunto de la revista: PSIQUIATRIA Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esquizofrenia Paranoide / Antipsicóticos Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Schizophr Res Asunto de la revista: PSIQUIATRIA Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos